Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720)
- PMID: 7815511
- PMCID: PMC188710
- DOI: 10.1128/JVI.69.2.1306-1309.1995
Induction of protective cytotoxic T cells to murine cytomegalovirus by using a nonapeptide and a human-compatible adjuvant (Montanide ISA 720)
Abstract
The use of synthetic peptides representing cytotoxic T-cell (CTL) epitopes for human vaccination requires the identification of a suitable adjuvant formulation. A single immunization with Montanide ISA720/tetanus toxoid/YPHFMPTNL protected mice against murine cytomegalovirus and induced epitope-specific CTL. Such formulations will find application in peptide-based CTL anti-viral vaccines.
Similar articles
-
Effect of natural sequence variation at the H-2Ld-restricted CD8+ T cell epitope of the murine cytomegalovirus ie1-encoded pp89 on T cell recognition.J Gen Virol. 1996 Oct;77 ( Pt 10):2615-23. doi: 10.1099/0022-1317-77-10-2615. J Gen Virol. 1996. PMID: 8887498
-
Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems.Vaccine. 1999 Apr 9;17(15-16):2009-19. doi: 10.1016/s0264-410x(98)00468-x. Vaccine. 1999. PMID: 10217601
-
Immunization of mice with vaccinia virus-M2 recombinant induces epitope-specific and cross-reactive Kd-restricted CD8+ cytotoxic T cells.J Virol. 1993 Jul;67(7):4086-92. doi: 10.1128/JVI.67.7.4086-4092.1993. J Virol. 1993. PMID: 7685408 Free PMC article.
-
Induction of protective CTL responses against the Plasmodium yoelii circumsporozoite protein by immunization with peptides.J Immunol. 1997 Oct 1;159(7):3424-33. J Immunol. 1997. PMID: 9317141
-
Prospects for T cell immunotherapy of tumours by vaccination with immunodominant and subdominant peptides.Ciba Found Symp. 1994;187:97-104; discussion 104-12. doi: 10.1002/9780470514672.ch7. Ciba Found Symp. 1994. PMID: 7796678 Review.
Cited by
-
The Breadth of Synthetic Long Peptide Vaccine-Induced CD8+ T Cell Responses Determines the Efficacy against Mouse Cytomegalovirus Infection.PLoS Pathog. 2016 Sep 16;12(9):e1005895. doi: 10.1371/journal.ppat.1005895. eCollection 2016 Sep. PLoS Pathog. 2016. PMID: 27637068 Free PMC article.
-
Phase I/II study of immunotherapy with T-cell peptide epitopes in patients with stage IV melanoma.Cancer Immunol Immunother. 2005 Mar;54(3):208-18. doi: 10.1007/s00262-004-0587-8. Epub 2004 Sep 21. Cancer Immunol Immunother. 2005. PMID: 15449035 Free PMC article. Clinical Trial.
-
Prime-boost-type PspA3 + 2 mucosal vaccine protects cynomolgus macaques from intratracheal challenge with pneumococci.Inflamm Regen. 2023 Nov 15;43(1):55. doi: 10.1186/s41232-023-00305-2. Inflamm Regen. 2023. PMID: 37964391 Free PMC article.
-
Intratumoral checkpoint subversion as a strategy for minimizing adverse effects: Harvesting the power of TILs without harvesting TILs.Oncoimmunology. 2014 Jan 3;3:e27580. doi: 10.4161/onci.27580. eCollection 2014. Oncoimmunology. 2014. PMID: 25339995 Free PMC article. No abstract available.
-
Suppression of murine cytomegalovirus (MCMV) replication with a DNA vaccine encoding MCMV M84 (a homolog of human cytomegalovirus pp65).J Virol. 2000 Apr;74(8):3696-708. doi: 10.1128/jvi.74.8.3696-3708.2000. J Virol. 2000. PMID: 10729145 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases